DBTX Stock Overview
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Decibel Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.34 |
| 52 Week High | US$5.78 |
| 52 Week Low | US$1.61 |
| Beta | 0 |
| 1 Month Change | 62.93% |
| 3 Month Change | -9.73% |
| 1 Year Change | -22.69% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -81.48% |
Recent News & Updates
Shareholder Returns
| DBTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 29.0% | 0.8% | 2.8% |
| 1Y | -22.7% | 7.1% | -9.2% |
Return vs Industry: DBTX underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: DBTX underperformed the US Market which returned -9.2% over the past year.
Price Volatility
| DBTX volatility | |
|---|---|
| DBTX Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DBTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: DBTX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 62 | Laurence Reid | https://www.decibeltx.com |
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company’s lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene.
Decibel Therapeutics, Inc. Fundamentals Summary
| DBTX fundamental statistics | |
|---|---|
| Market Cap | US$82.42m |
| Earnings (TTM) | -US$59.97m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs DBTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DBTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$59.97m |
| Earnings | -US$59.97m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DBTX perform over the long term?
See historical performance and comparison